Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494390 | 0.86 | MEN1 (0.41) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL5223996 | 0.85 | MEN1 (0.47) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL6478801 | 0.82 | ADORA3 (0.49) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL3520995 | 0.77 | KMT2A (0.54) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL5224357 | 0.77 | KMT2A (0.47) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL6625684 | 0.76 | MEN1 (0.45) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL6491520 | 0.76 | KMT2A (0.46) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL6478489 | 0.74 | LMNA (0.45) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL5460979 | 0.74 | ADORA3 (0.46) | KMT2AMEN1LMNAHTTALDH1A1 | |
| SCHEMBL6480798 | 0.74 | ALDH1A1 (0.48) | KMT2AMEN1LMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390349-B1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-20070249669-A1 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2007-10-25 | — | — | US | disclosed |
| EP-1740580-A2 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES , PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sanofi-Aventis (FR) | 2007-01-10 | — | — | EP | disclosed |
| US-6969723-B2 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI - AVENTIS (FR) | 2005-11-29 | — | — | US | disclosed |
| WO-2005100320-A2 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-AVENTIS (FR) | 2005-10-27 | — | — | WO | disclosed |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | SANOFI (FR) | 2004-09-23 | — | — | US | disclosed |
| EP-1390349-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2004-02-25 | — | — | EP | disclosed |
| WO-2002096879-A1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249669-A1 | CRYSTALLINE 2-AMINO-3-CYANOQUINOLINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SFPQ, ADRB3, KCNQ3 | KMT2A 2114/4885MEN1 907/4885LMNA 953/4885 |
| US-20040186133-A1 | Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands | ADORA3, ADORA1, ADORA2A | KMT2A 2739/4885MEN1 3078/4885LMNA 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.